secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001104659-24-076037
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed enters $150M ATM equity program with Leerink Partners, terminates prior ATM
--------------------------------------------------------------------------------

- New at-the-market sales agreement with Leerink Partners LLC authorizes sale of up to $150M in common shares.
- Agent commission capped at 3.0% of gross proceeds; company has no obligation to sell shares.
- Prior Controlled Equity Offering agreement with Cantor Fitzgerald and Oppenheimer terminated on May 28, 2024.
- Company may suspend or terminate the new ATM facility at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000110465924076037/0001104659-24-076037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000110465924076037/tm2416299d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-076037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer